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Abstract 
We proposed a prototype facility for the generation of radioisotopes with accelerator neutrons by 
deuterons. The neutrons are produced by natC(d,n) with 40 MeV 2 mA deuteron beams, and about 8.1 
TBq/week of 99Mois produced by irradiating an enriched 100Mo sample with the neutrons.  High-quality 
99mTc can be separated from an irradiated 100MoO3 sample by thermo-chromatographic separation. In this 
contribution we present the system to produce medical radioisotopes, such as 99Mo, 90Y, and 67Cu, and 
experimental studies on 99Mo and 67Cu produced by using accelerator neutrons. 
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1. Introduction 
Many radioisotopes (RIs) produced in reactors or accelerators have been used in medicine, research, and industry. 
In fact, 99mTc, the daughter nuclide of 99Mo with a half-life (T1/2) of 66 h, is the most common RI used in nuclear 
medicine diagnosis. In Japan, about 0.9 million diagnostic procedures are carried out using 99mTc separated from 
99Mo; all the 99Mo is imported. A reliable supply of 99Mo, therefore, is the key issue to ensure the routine  
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application of 99mTc. 99Mo has been mostly produced with a high specific activity by the fission reaction of highly 
enriched 235U (HEU) in five research reactors in the world. However, a number of recent incidents of the reactors 
caused the shortage of 99Mo [1]. A volcano eruption on Iceland also reminded us of the risk of relying on a small 
number of 99Mo production facilities. The shortage of 99Mo has stimulated discussions on the medium- and long-
term supplies of 99Mo worldwide [2]. In fact, many efforts are being made for the domestic production of 99Mo or 
99mTc by developing an alternative production method of medical radioisotopes without HEU. We proposed a new 
99Mo production route via 100Mo(n,2n)99Mo using neutrons from an accelerator  [3]. 
In this paper we present briefly the proposed 99Mo production method, the separation method of high-quality 
99mTc using 99Mo with a low-specific activity produced by accelerator neutrons, a prototype facility for the 
Generation of Radioisotopes with Accelerator Neutrons by Deuterons (GRAND), and the capability of the facility 
for producing other medical radioisotopes, such as 90Y, 64Cu, and 67Cu. 
 
2. Proposed 99Mo Production Method and Intense Accelerator Neutrons 
  
Many production methods of 99Mo and/or 99mTc in accelerators have been proposed and studied. Feasibility 
studies have been carried out for the direct production method of 99mTc via the 100Mo(p,2n)99mTc reaction [4] and for 
the production of 99Mo by the 100Mo(J,n)99Mo reaction [5,6]. Challenging production methods by the 
235U(n,fission)99Mo or 98Mo(n,J)99Mo reactions using spallation neutrons, and by the 238U(J,fission)99Mo reaction 
using bremsstrahlung photons from electron accelerators have also been studied. Contrary to these studies fast 
neutrons from an accelerator have not yet been used for producing any radioisotopes. We noticed that fast neutrons 
could produce a large quantity of high-quality 99Mo with a minimum level of radioactive wastes; this is because the 
cross section of the 100Mo(n,2n)99Mo reaction is quite large at 11d En d18 MeV, about 1.5 barn, but the cross 
sections of the (n,D), (n,n’p), and (n,p) reactions on 100Mo to produce impurity radionuclides other than 99Mo are less 
than a few mb at En a 14 MeV [3], as shown in Fig. 1. (En is neutron energy). Because of a small yield of impurity 
radionuclides, radioactive waste produced during separation process of 99mTc from 99Mo would not be a serious 
problem, and an irradiated enriched 100Mo sample can be recycled. Note that the enrichment of 100Mo can be 
between 90 and 95% and is not necessary as high as at above 99%, since we irradiate 100Mo with neutrons. High 
penetration power of fast neutrons in a sample allows us to use a large amount of 100Mo sample, and/or to co-
produce other medical isotopes at the same time [7]. A recovery efficiency of 30 g MoO3 sample was shown to be 
high at above 95%. The potential for other isotopes co-production provides an indication of the economic 
sustainability, demand risk mitigation and the ability to avoid creating other isotope shortage [8]. 
Recent progress of accelerator technology can provide intense neutrons of 11–18 MeV, necessary to produce 
99Mo with a good specific activity. In fact, neutrons with an intensity of 1015 n/s with a most probable energy of 14 
MeV will be produced by the natC(d,n) reaction using 40 MeV 5 mA deuterons at SPIRAL2 located at GANIL [9]. A 
neutron converter, which should withstand the high power of the 40 MeV 5 mA deuteron beams, has also been 
developed using a rotating carbon converter in the SPIRAL2 project [10]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Neutron energy dependence of cross sections {V(b)}          Fig. 2. A calculated yield distribution of 99Mo.  
of neutron induced reaction on 100Mo in units of barn.                    (100Mo thickness vs 100Mo radius)     
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On the basis of the developments mentioned above, we calculated the angular and thickness distributions of the 
produced 99Mo with respect to the deuteron beam direction, as shown in Fig. 2, and the yield of 99Mo  [11]. Here we 
used the latest data of neutrons from the natC(d,n) reaction, assuming 40 MeV 5 mA deuteron beams, and the 
evaluated cross section of 100Mo(n,2n)99Mo given in the Japanese Evaluated Nuclear Data Library (JENDL-4.0). 
Note that the sample was placed 2 cm downward from the carbon target, and the deuteron beam size was assumed to 
be a point. The 99Mo yield should be noted to be mostly distributed in a narrow region at an extremely forward angle 
with respect to the deuteron beam direction and within a sample thickness of about 4 cm, which indicate that the 
emitted neutrons are effectively used to produce a specific activity of 99Mo as high as possible. About 8.1 TBq of 
99Mo, which meets about 20  25 % of the 99Mo demand in Japan, was calculated for an irradiation time of two days 
for a 100Mo sample with a thickness of 2 cm and a radius of 2 cm (251 g 100Mo). Here, we took into account 
reduction of the 99Mo activity by about 10  20 % during separation process of 99mTc from 99Mo. 
 
3. 99Mo Production and Separation of 99mTc from 99Mo 
 
In the medical use of 99mTc the safety and efficacy of the 99mTc radiopharmaceutical preparation should be 
assured. In fact, the United States Pharmacopeia (USP) contains the requirements concerning the radionuclide purity 
and radiochemical purity of 99mTc [12]. The quality of 99mTc obtained from the fission product 99Mo, which has a 
specific-activity of a370 TBq/(g 99Mo), meets the requirements.  However, a specific-activity of 99Mo produced by 
any alternative production method in accelerators (except fission reaction of uranium) is as low as about 37 GBq/(g 
100Mo) [13]. Hence, we performed an experimental study of the quality of 99mTc for 99Mo produced by using the 
accelerator neutrons. 
99Mo activity was produced by irradiating a natural MoO3 pellet sample with a14 MeV neutrons, which were 
provided by the 3H(d,n)4He reaction at the Fusion Neutronics Source of the Japan Atomic Energy Agency (JAEA) 
[14]. In order to separate 99mTc from 99Mo of a low-specific activity, we have employed thermo-chromatographic 
separation, in which there remain several challenging problems: the separation efficiency of 99mTc is low, diminishes 
markedly with repeated milking tests at a constant furnace temperature, and decreases with an increasing mass of 
MoO3 loaded into a sublimation furnace at a time [15]. The separation of 99mTc from an irradiated molten MoO3 
sample was performed at the Radioisotope Production Facility at JAEA. We used an electric furnace, as shown in 
Fig. 3 [16]. Here, Tc and Mo oxides volatilized from a molten MoO3 sample are condensed in different temperature 
zones along a column in a furnace, and thereby we could obtain 99mTc with a high radioactive concentration free 
from any chemical impurities. Hence, when we use an enriched 100Mo sample, we could recycle the sample. 
 
 
 
 
 
 
 
 
 
 
  Fig. 3. A schematic view of electric furnace used in thermo chromatographic separation of 99mTc from Mo.  
 
 
The separation efficiency of 99mTc from a molten MoO3 sample was studied using cadmium zinc telluride (CZT) J-ray detectors (1 u 1 u 1 cm3) having an energy resolution of 11 keV at 141 keV to identify the decays of 99Mo and 
99mTc, and thereby to determine the separation efficiency. So far, several studies were undertaken to measure the 
separation efficiency by using a molten MoO3 sample [15,17,18]. Christian et al. used a molten MoO3 sample with a 
thickness of 0.8 mm in order to obtain a high separation efficiency of 99Tc, a pure E-emitter [18]. Having such a thin 
sample is, however, not desirable for large-scale production. We also aimed to derive the diffusion coefficients of 
99mTc from molten MoO3 samples, which would provide information concerning the release mechanism of 99mTc. 
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High separation efficiencies of about 90 and 70% have been obtained through a repeated milking process by the 
thermo-separation of 99mTc from 10 and 14 g molten MoO3 samples with thicknesses of 4.0 and 8.8 mm, and high 
average diffusion coefficients of 4.5u105 and 1.5u104 cm2/s were obtained for 4.0 and 8.8 mm thick samples, 
respectively. 99mTc, therefore, could diffuse very rapidly in the thick molten sample within a reasonable furnace 
heating time of 15 to 30 min, and subsequently evaporate from the sample [19]. 
After the separation of 99mTc we took a J-ray spectrum of the separated 99mTc by a Ge detector to determine the 
activity of any impurity radioisotopes, such as 99Mo, 97Zr and 97Nb. These impurities were shown to be less than 
0.01% of that of the 141 keV J-ray (99mTc). Labelling efficiency of 99mTc, an important factor in the compounding 
and dispensing of radiopharmaceuticals, was shown to be higher than 99% by formulating a radiopharmaceutical by 
using commercially available methylene diphosphonate (MDP) kits. Both results of impurity activities and labeling 
efficiency fulfilled the United States Pharmacopeia (USA) requirement of the radionuclide purity of 99mTc. 
 
4. Production of Other Medical Radioisotopes 
 
A radiopharmaceutical agent containing a radionuclide 90Y (T1/2 = 64 h), a pure E-ray emitter, has been used for 
cancer therapy {90Y-ibritumomab tiuxetan (Zevarin)}, and 67Cu (T1/2 = 61.8 h) is a promising radionuclide to treat 
small distant metastases in radioimmunotherapy, and 64Cu (T1/2 = 12.7 h) is a promising radionuclide suitable for 
labelling many radiopharmaceuticals for PET imaging. Note that since 67Cu emits low-energy J-rays, it can be used 
simultaneously for diagnostic imaging and internal therapy. Currently, 90Y for medical use is obtained from the 
90Sr/90Y generator, and is imported into Japan. The generally adopted route of 64Cu production is 64Ni(p,n)64Cu in a 
compact cyclotron using an enriched 64Ni. (Natural abundance of 64Ni is 0.93%). 67Cu is currently produced by the 
68Zn(p,2p)67Cu reaction using high energy proton accelerators [20]. We proposed another routes to produce 90Y via 
90Zr(n,p)90Y, 64Cu via 64Zn(n,p)64Cu, and 67Cu via 68Zn(n,np+d)67Cu [21] using fast neutrons from an accelerator by 
noting that the (n,p), (n,np+d), and (n,D) of a sample nucleus with a medium-weight mass (<100) has a sizable cross 
section of from a50 to a500 mb at a 10 < En < 18 MeV. In fact, we took a J-ray spectrum of 67Cu, which was 
produced by the 68Zn(n,np+d)67Cu reaction using neutrons form natC(d,n) reaction at Ed = 40 MeV, as shown in Fig. 
4, and showed that the 67Cu has a much higher radionuclide purity compared to the purity obtained in previous 
studies [22]. In fact, the impurity radionuclides, such as 64Cu and 65Zn, produced in the 68Zn(n,np+d)67Cu reaction 
were less than one six-hundredth and 6.7u104, respectively, compared with those produced by the 68Zn(p,2p)67Cu 
reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. A J-ray spectrum of an irradiated 68ZnO taken 4.5 h after end of irradiation. The J-ray peaks come from the decays of  
67Cu (open circles), 65Ni (filled circle), 66Ni (filled square) and 69mZn (filled diamond).  
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5. Facility for GRAND 
 
Since we could obtain high-quality 99mTc, which fulfilled the USP requirement of the radionuclide purity of 99mTc, 
from 99Mo produced by using accelerator neurons, and produce 90Y, 64Cu, and 67Cu with good-quality using the 
neutrons, we have proposed for a prototype facility for the generation of radioisotopes with accelerator neutrons by 
deuterons (GRAND) [7]. The facility consists of an azimuthally varying field (AVF) cyclotron, which can provide a 
deuteron beam intensity of 2 mA (but not 5mA for the prototype) and a hot laboratory, where one can recover high-
quality carrier-free medical radioisotopes from a neutron irradiated sample. Note that a fixed radiofrequency 
cyclotron is robust in operation, compact in size, and relatively cheap compared to a linear accelerator. An 
accelerator production company, such as Sumitomo Heavy Industry having experiences for the construction of AVF 
cyclotron for a 90 MeV proton beam, has constructed an AVF cyclotron, which can provide a 30 MeV 1mA H 
beam for Boron Neutron Cancer Therapy (BNCT).   
 
6. Conclusions 
 
  The generation of radioisotopes with accelerator neutrons by deuterons (GRAND) is shown to be one of powerful 
method for producing medical radioisotopes. In fact, the proposed system on the basis of the GRAND has unique 
features to produce a wide variety of radioisotopes, including 99Mo. Further developments to generate higher 
intensity accelerator neutrons with En t 10 MeV are highly anticipated to produce various high-quality medical 
radioisotopes. Obviously the cost of raw materials (e.g. enriched 100Mo), the accelerator facilities or their 
modifications, the equipment to separate the radionuclides, and the annual manpower costs of realizing a particle 
accelerator approach to generate 99Mo would have to be factored into the decision to develop such a process. 
However, this was not part of the intent of this paper.  
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